281 related articles for article (PubMed ID: 28530894)
1. Preventing herpes zoster through vaccination: New developments.
Le P; Sabella C; Rothberg MB
Cleve Clin J Med; 2017 May; 84(5):359-366. PubMed ID: 28530894
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.
de Boer PT; van Lier A; de Melker H; van Wijck AJM; Wilschut JC; van Hoek AJ; Postma MJ
BMC Med; 2018 Dec; 16(1):228. PubMed ID: 30518427
[TBL] [Abstract][Full Text] [Related]
3. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia.
Betts RF
J Am Acad Dermatol; 2007 Dec; 57(6 Suppl):S143-7. PubMed ID: 18021866
[TBL] [Abstract][Full Text] [Related]
4. Vaccination: a new option to reduce the burden of herpes zoster.
Mick G
Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
[TBL] [Abstract][Full Text] [Related]
5. Shingles (Herpes Zoster) Vaccine (Zostavax(®)): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia.
Keating GM
BioDrugs; 2016 Jun; 30(3):243-54. PubMed ID: 27189459
[TBL] [Abstract][Full Text] [Related]
6. Herpes zoster vaccine: a protection for the elderly.
Di Pietro A; Facciolà A; Visalli G
Ann Ig; 2018; 30(4 Supple 1):23-27. PubMed ID: 30062376
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
Le P; Rothberg MB
Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
[TBL] [Abstract][Full Text] [Related]
8. Zostavax : a subcutaneous vaccine for the prevention of herpes zoster.
Doan HQ; Ung B; Ramirez-Fort MK; Khan F; Tyring SK
Expert Opin Biol Ther; 2013 Oct; 13(10):1467-77. PubMed ID: 23984934
[TBL] [Abstract][Full Text] [Related]
9. Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.
Chen LK; Arai H; Chen LY; Chou MY; Djauzi S; Dong B; Kojima T; Kwon KT; Leong HN; Leung EM; Liang CK; Liu X; Mathai D; Pan JY; Peng LN; Poblete ER; Poi PJ; Reid S; Tantawichien T; Won CW
BMC Infect Dis; 2017 Mar; 17(1):213. PubMed ID: 28298208
[TBL] [Abstract][Full Text] [Related]
10. Herpes Zoster and Its Prevention by Vaccination.
Johnson RW; Levin MJ
Interdiscip Top Gerontol Geriatr; 2020; 43():131-145. PubMed ID: 32305975
[TBL] [Abstract][Full Text] [Related]
11. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.
You JHS; Ming WK; Lee CF; Tsang OT; Chan PK
Vaccine; 2018 Jul; 36(31):4610-4620. PubMed ID: 29958739
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.
Curran D; Patterson B; Varghese L; Van Oorschot D; Buck P; Carrico J; Hicks K; Lee B; Yawn B
Vaccine; 2018 Aug; 36(33):5037-5045. PubMed ID: 30017145
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
14. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R
Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911
[TBL] [Abstract][Full Text] [Related]
15. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
[TBL] [Abstract][Full Text] [Related]
16. [Herpes Zoster and its prevention in Italy. Scientific consensus statement].
Franco E; Gabutti G; Bonanni P; Conversano M; Stefano Valente ME; Ferro A; Icardi G; Antonio Volpi ML; Maggi S; Rossi A; Scotti S; Vitale F; Greco D;
Ig Sanita Pubbl; 2014; 70(1):111-27. PubMed ID: 24770367
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine.
Pieters Z; Ogunjimi B; Beutels P; Bilcke J
Pharmacoeconomics; 2022 Apr; 40(4):461-476. PubMed ID: 35094374
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
[TBL] [Abstract][Full Text] [Related]
19. Herpes Zoster Vaccination: Controversies and Common Clinical Questions.
Van Epps P; Schmader KE; Canaday DH
Gerontology; 2016; 62(2):150-4. PubMed ID: 26184711
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
Le P; Rothberg MB
JAMA Intern Med; 2018 Feb; 178(2):248-258. PubMed ID: 29297049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
